Get started
Vaxart, Inc. - Common StockVaxart, Inc. - Common StockVaxart, Inc. - Common Stock

Vaxart, Inc. - Common Stock

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

VXRT chart


Full chart

VXRT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪136.76 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.4089 USD
Net income (FY)
‪−82.47 M‬ USD
Revenue (FY)
‪7.38 M‬ USD
Shares float
‪225.47 M‬
Beta (1Y)
2.83

Employees


Employees (FY)
125
Change (1Y)
−52 −29.38%
Revenue / Employee (1Y)
‪59.03 K‬ USD
Net income / Employee (1Y)
‪−659.72 K‬ USD

About Vaxart, Inc. - Common Stock


Sector
Health Technology
Industry
Biotechnology
CEO
Steven Lo
Website
vaxart.com
Headquarters
South San Francisco
Founded
2004
FIGI
BBG000DR0RZ7
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VXRT news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VXRT is 0.6088 USD — it has increased by 1.26% in the past 24 hours. Watch Vaxart, Inc. - Common Stock stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vaxart, Inc. - Common Stock stocks are traded under the ticker VXRT.
VXRT stock has risen by 6.27% compared to the previous week, the month change is a 0.13% rise, over the last year Vaxart, Inc. - Common Stock has showed a 4.68% increase.
We've gathered analysts' opinions on Vaxart, Inc. - Common Stock future price: according to them, VXRT price has a max estimate of 8.00 USD and a min estimate of 2.50 USD. Watch VXRT chart and read a more detailed Vaxart, Inc. - Common Stock stock forecast: see what analysts think of Vaxart, Inc. - Common Stock and suggest that you do with its stocks.
VXRT reached its all-time high on May 5, 2004 with the price of 1,181.5175 USD, and its all-time low was 0.2543 USD and was reached on Sep 25, 2019. View more price dynamics on VXRT chart.
See other stocks reaching their highest and lowest prices.
VXRT stock is 5.59% volatile and has beta coefficient of 2.83. Track Vaxart, Inc. - Common Stock stock price on the chart and check out the list of the most volatile stocks — is Vaxart, Inc. - Common Stock there?
Today Vaxart, Inc. - Common Stock has the market capitalization of ‪136.76 M‬, it has decreased by −3.65% over the last week.
Yes, you can track Vaxart, Inc. - Common Stock financials in yearly and quarterly reports right on TradingView.
Vaxart, Inc. - Common Stock is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
VXRT earnings for the last quarter are −0.06 USD per share, whereas the estimation was −0.10 USD resulting in a 40.30% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about Vaxart, Inc. - Common Stock earnings.
Vaxart, Inc. - Common Stock revenue for the last quarter amounts to ‪4.93 M‬ USD, despite the estimated figure of ‪1.93 M‬ USD. In the next quarter, revenue is expected to reach ‪20.78 M‬ USD.
VXRT net income for the last quarter is ‪−14.08 M‬ USD, while the quarter before that showed ‪−16.47 M‬ USD of net income which accounts for 14.49% change. Track more Vaxart, Inc. - Common Stock financial stats to get the full picture.
No, VXRT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 125.00 employees. See our rating of the largest employees — is Vaxart, Inc. - Common Stock on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vaxart, Inc. - Common Stock EBITDA is ‪−67.20 M‬ USD, and current EBITDA margin is ‪−1.07 K‬%. See more stats in Vaxart, Inc. - Common Stock financial statements.
Like other stocks, VXRT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaxart, Inc. - Common Stock stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vaxart, Inc. - Common Stock technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vaxart, Inc. - Common Stock stock shows the sell signal. See more of Vaxart, Inc. - Common Stock technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.